Research Article
A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles Using Pathway-Drug Network
Table 10
Betweenness of promising drug candidates on the validation network.
| Rank | Drug name | Betweenness |
| 1 | Tamoxifen | 172 | 2 | Paclitaxel | 37 | 3 | Doxorubicin | 32 | 4 | Camptothecin | 13 | 5 | Exemestane | 13 | 6 | Fulvestrant | 12 | 7 | Methotrexate | 10 | 8 | Vinblastine | 6 | 9 | Megestrol | 6 | 10 | Aminoglutethimide | 2 | 11 | Letrozole | 2 | 12 | MS-275 | 2 | 13 | GW-8510 | 0 | 14 | Phenoxybenzamine | 0 | 15 | Tyrphostin_AG-825 | 0 | 16 | Alsterpaullone | 0 | 17 | Celastrol | 0 |
|
|
Known breast cancer drug. Potential drug candidate for repositioning.
|